Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFNγ production

Antigen spreading elicited by adoptive cell transfer

In addition to the use of dual-specific T cells or cocktail treatment with CAR T cells to address tumor antigenic heterogeneity and antigen loss^6,7, accumulating evidence supports the emerging concept of triggering the endogenous immune system to establish an effective anti-tumor response. Antigen spreading (AS), a mode of activation of the endogenous immune system, is elicited after primary therapy-induced tumor lysis and results in the release of secondary tumor antigens other than the CAR T cell targeted epitope. Subsequently, antigen-presenting cells (APCs), such as dendritic cells (DCs), take up these secondary antigens and induce an endogenous T cell response, thereby eliminating tumor cells⁸. In the context of ACT, approaches using CAR T cells to induce endogenous T cell responses may be a promising strategy to overcome antigen escape.

In fact, AS into the support anti-tumor response of CAR T cells has been demonstrated in recent studies. In the July 2023 issue of Cell, Ma et al.³ reported that vaccine-boosting increases the metabolic fitness of CAR T cells and facilitates communication between CAR T cells and the endogenous immune system, thus inducing and maintaining an AS response in vivo. In that study, an amph-ligand-based vaccine containing a ligand for a selected CAR linked to a hydrophobic phospholipid tail via a polyethylene glycol spacer was designed. After co-injection of the amph-ligand-based vaccine with a suitable adjuvant—such as the stimulator of interferon genes (STING) agonist cyclic di-GMP, the Toll-like receptor (TLR) 7/8 agonist Resiquimod, or the TLR9 agonist CpG—the amph-ligands bind albumin in the interstitial fluid, migrate to draining lymph nodes (dLNs), and are transferred to cell membranes and subsequently decorate the surfaces of DCs and macrophages. DCs are simultaneously activated by the co-injected adjuvant in dLNs, thus increasing costimulatory receptor expression and cytokine production. Subsequently, CAR T cells, after encountering ligand-decorated, activated DCs, are stimulated to shift their metabolism toward oxidative phosphorylation, in a manner mimicking the activation of natural T cells. Consequently, CAR T cells expand and show enhanced effector function. In murine syngeneic tumor models, DCs are recruited by vaccine-boosting of CAR T cells into the tumor mass, thus augmenting antigen uptake and processing capacity, and magnifying the priming of endogenous T cell anti-tumor responses. This process may eliminate antigenic heterogeneous tumor cells through AS of endogenous T cells. Mechanistically, CAR T cell derived IFNγ after vaccine boosting plays a critical role in AS initiation. Reciprocally, IFNγ stimulated DCs enhance the secretion of IL-12, which in turn further amplifies autocrine IFNγ secretion by CAR T cells. The concept of IFNγ signaling promoting endogenous T cell immunity has also been confirmed in syngeneic GBM transplanted murine models treated with anti-IL13Ra2 CAR T cells⁹. CAR T cells derived from IFNγ−/− mice exhibit poorer anti-tumor activity in vivo than CAR T cells generated from wild type (WT) mice, thus indicating that IFNγ deficiency dampens the anti-tumor effects of CAR T cells in vivo.

To achieve AS in the setting of ACT to compete against antigen escape of heterogeneous tumor cells, several studies have focused on CAR T cells engineered with additional immunostimulatory factors, such as FLT3L¹⁰ and CD40L¹¹. These studies have provided evidence that AS increases anti-tumor activity.

The conditions associated with the production of high levels of IFNγ by CAR T cells include (1) activation of APCs by a suitable adjuvant; (2) CAR ligand decoration or presentation on APCs; (3) CAR T cells encountering these activated and decorated APCs in dLNs via the CAR-ligand axis and costimulatory factor-receptor axis, and being activated in a manner mimicking the activation of natural T cells; and (4) that IL-12 secretion from activated DCs stimulating CAR T cells to further maintain high IFNγ expression. Moreover, the activation of APCs plays a crucial role in AS in cancer treatments, such as ACT. On this basis, AS can be elicited in the setting of tumor therapy with CAR T cells.

IFNγ: a master initiator triggering pleiotropically endogenous anti-tumor immunity

IFNγ, a key proinflammatory cytokine produced by activated CAR T cells, plays an important role in promoting endogenous immune cell infiltration to tumor masses and subsequent reprogramming^3,9. For example, IFNγ promotes the recruitment and activation of cytotoxic T cells, and polarization of CD4⁺ T cells into T helper (Th) 1 cells. In addition, amph-ligand based vaccine boosted CAR T cell-derived IFNγ upregulates DC-recruiting chemokine expression in tumors, thereby increasing DC infiltration and activation, and eliciting an AS response that eliminates CAR-target antigen-negative tumor cells³. Moreover, IFNγ, together with IL-12, secreted by activated DCs, promotes the differentiation of naïve T cells into Th1 cells^12,13.

In addition, IFNγ has been reported to activate macrophages^14,15. Alizadeh et al.⁹ have shown that IFNγ produced by anti-IL13Ra2 CAR T cells from a mouse model of GBM endows intratumoral myeloid cells with anti-tumor activity. The frequency of MHC I⁺/MHC II⁺ and CD86⁺ macrophage activation is significantly upregulated in tumor bearing mice treated with CAR T^WT cells rather than CAR T^IFNγ−/− cells; nevertheless, the frequency of intratumoral M2-type macrophages is higher in mice treated with CAR T^IFNγ−/− cells⁹. Another recent study has indicated that IFNγ derived from CD4⁺ T cells either directly kills IFNγ-sensitive tumor cells or induces intratumoral myeloid cells to become iNOS-expressing tumoricidal types¹⁶. A highly specific iNOS inhibitor has been found to abrogate the anti-tumor activity of a CD4 based treatment (involving co-infusion of CD4⁺ TCR T cells, a vaccine comprising the recombinant adenovirus AD-PT encoding the TCR-target antigen, and innate stimulators that activate innate immunity through TLR3 and TLR9) in mice bearing MHC I/II-deficient IFNγ-unresponsive melanoma cells preconditioned with cyclophosphamide. These results indicated that IFNγ derived from CAR T cells or TCR T cells activates myeloid cells to eliminate tumor cells.

Thus, CAR T cell-derived IFNγ plays a crucial role in promoting endogenous immunity, including AS and myeloid cell activation, and further prevents tumor antigenic heterogeneity, as well as antigen loss mediated tumor escape and recurrence (Figure 1).

• Download figure
• Open in new tab
• Download powerpoint

Figure 1

Schematic overview of reciprocal activation of CAR T cells with antigen-presenting cells triggering a widespread endogenous anti-tumor immune response. (A) CAR/TCR ligand-decorated DCs activated through vaccine or adenovirus, and vaccine adjuvants such as STING or TLR agonists, stimulate CAR T/TCR T cell activation and expansion in lymph nodes. (B) Activated CAR T/TCR T cells migrate into the tumor mass and kill CAR/TCR-targeted antigen-positive tumor cells. CAR T/TCR T cells secrete IFNγ, thus inducing DC recruitment and activation, and secondary tumor antigen uptake, and activating antigen spreading. Meanwhile, IFNγ stimulates myeloid cell polarization into iNOS-expressing tumoricidal myeloid cells. Created with Biorender.com.

While strengthening endogenous immunity, IFNγ does not affect tumor angiogenesis³ but promotes PD-L1 expression in tumor cells, thus leading to lymphocyte dysfunction through the PD-1-PD-L1 axis^17,18. Multiple factors, such as expression levels of IFNγ and its receptor on tumor cells, suggest that IFNγ mediates the expression of PD-L1 in tumors^17–20. Whether enhanced endogenous immunity derived from IFNγ secreted by CAR T cells counteracts lymphocyte dysfunction remains to be further confirmed.

Clinical translation

Tumor-associated antigen is commonly used as a target for CAR T cells in solid tumors, but its heterogeneous expression impairs the efficiency of CAR T cell therapy. Effective approaches to combat antigenic heterogeneity and antigen loss are highly valuable in increasing the efficacy of CAR T cells in solid tumors. Indeed, a variety of approaches have been reported to reinforce the efficacy of CAR T cells against solid tumors, by potentiating CAR T cells, other host immune cells, or both^3,10,11. Observations from recent studies suggest that the activation of endogenous immunity may extend the anti-tumor efficacy of CAR T cells by overcoming heterogeneous antigen expression on tumor cells.

Promoting endogenous immunity to enhance the anti-tumor activity of CAR T cells is anticipated in clinical trials. AS in CAR T cell therapy rarely has adequate treatment effects, possibly because the activation of DCs is insufficient for the initial cross-activation of endogenous T cells and effector T cell recruitment into the tumor microenvironment. Over-expression of FLT3L¹⁰ and CD40L¹¹ on CAR T cells, and co-infusion with vaccine adjuvants such as STING-ligand, TLR 7/8 agonist, and TLR9 agonist³, may induce activation of DCs, thereby stimulating the endogenous immune system to assist in CAR T cell anti-tumor activity. Furthermore, the use of armed CAR T cells with sustained expression of IFNγ in an antigen-dependent manner to activate endogenous immunity and elicit tumor destruction is also valuable in tumor treatment.

Summary

ACT with CAR T cells has been highly successful in the treatment of relapsed/refractory CD19⁺ B cell acute lymphoblastic leukemia and lymphoma. Several issues, including limited tumor infiltration, functionality, and persistence, limit the benefits of CAR T cell therapy for patients with solid tumors. Although a variety of strategies have recently been developed to enhance the anti-tumor activity of CAR T cells for solid tumors, pre-existing antigenic heterogeneity and antigen loss during treatment greatly restrain CAR T cell efficacy. Accumulating evidence highlights that promoting endogenous immunity, including AS and myeloid cell activation, may enhance the overall treatment response in the ACT setting. Although this modality is currently in the proof-of-concept stage, it may support a wide range of clinical applications in patients with solid tumors.

Author contributions

Conceived and designed the analysis: Yao Wang, Weidong Han.

Collected the data: Zhiqiang Wu, Yuting Lu.

Wrote the paper: Yelei Guo, Chuan Tong.